SYSTEMIC LUPUS ERYTHEMATOSUS

This early study tests a new drug called HN2302, which aims to create CAR-T cells inside the body to target and control autoimmune diseases like lupus and scleroderma. The trial will enroll 12 adults to check safety and see if the treatment works. It is a first step, so results w…

This early-stage trial is evaluating an investigational drug called QLS2404, given as an injection, to see if it is safe and tolerable. The study first tests single doses in healthy volunteers, then moves to multiple doses in people with systemic lupus erythematosus or primary Sj…

This early-stage trial is testing an experimental drug called SNC116 in people with refractory systemic lupus erythematosus (SLE), a form of lupus that hasn't improved with standard treatments. The study aims to see if a single intravenous infusion of SNC116 is safe and tolerable…

This phase 1 trial is testing an experimental drug called ATG-201 in adults with systemic lupus erythematosus, systemic sclerosis, or Sjögren's disease. ATG-201 is designed to bind to specific proteins on immune cells, potentially quieting the overactive immune response that driv…

This study offers continued access to anifrolumab (Saphnelo) for people with systemic lupus erythematosus, systemic sclerosis, or myopathies who completed a prior anifrolumab trial and are still benefiting from the drug. Participants receive the same treatment as before, while re…

This study tests anifrolumab, a drug for systemic lupus erythematosus (SLE), given either as a shot under the skin or through an IV. The goal is to see how the body processes the drug and check its safety. About 92 adults with lupus will take part.

This early-stage study is testing a new treatment called C-CAR168 for people with autoimmune diseases like multiple sclerosis, lupus, and myasthenia gravis that have not improved with standard therapies. The treatment uses a patient's own immune cells, which are modified in a lab…

This study tests whether teprenone, a stomach-protecting drug, can reduce gastrointestinal damage caused by high-dose steroids in people with lupus. One hundred participants will be randomly assigned to take either teprenone or the standard acid-blocker omeprazole for 12 weeks. T…

This first-in-human study tests the safety of a new drug called HBM7020. It will first be given to healthy volunteers at low doses, then to people with moderate to severe autoimmune diseases like lupus, rheumatoid arthritis, scleroderma, and Sjögren's disease. The goal is to see …

This study tests anifrolumab, a drug already used in adults with lupus, in children aged 5 to 17. The goal is to see how the drug moves through the body and if it is safe. Twenty-four children with moderate to severe lupus will receive the drug as a shot under the skin, while con…

This early-phase trial tests an injection called KSVCBD, a type of CAR-T cell therapy, in 60 adults with severe autoimmune diseases like lupus and scleroderma. The goal is to see if it's safe and to get a first look at whether it might help control the disease. Participants recei…

This phase 2 trial is testing a new treatment called FT819 for people with lupus nephritis, a serious kidney complication of lupus. FT819 is made from donor immune cells that are engineered to target and destroy faulty B cells. The study will enroll 53 participants and aims to se…

This study tests whether regularly measuring the amount of mycophenolate mofetil in the blood helps more people with lupus kidney disease achieve kidney remission. One hundred adults with active lupus nephritis will be split into two groups: one gets standard dosing, the other ge…

This early-phase study tests a new mRNA drug that targets two proteins (CD19 and BCMA) on immune cells. The goal is to clear the faulty B cells and plasma cells that attack the body in autoimmune diseases. 27 adults aged 18-70 with relapsed or hard-to-treat autoimmune diseases wi…

This study compares two drugs, telitacicept and belimumab, for controlling systemic lupus erythematosus (SLE) in adults aged 18-65. Participants choose their treatment with their doctor, and researchers track how well each drug reduces lupus activity and kidney problems. The goal…

This early study tests a new drug called STR-P004 in 9 adults with immune-mediated kidney diseases. The goal is to see if the drug is safe and how the body processes it. Participants receive up to 8 infusions over 28 days, with possible dose increases. This is not a cure; it aims…

This early-phase study tests a new mRNA therapy that targets CD19, a protein on immune cells, to treat autoimmune diseases like lupus and immune anemia. The treatment uses lipid nanoparticles to deliver mRNA that helps the body clear harmful B cells. About 47 participants aged 14…

This early-phase study tests a new drug called WGb-0301 for people with autoimmune diseases (like lupus or autoimmune hepatitis) that haven't responded to standard treatments. The drug uses mRNA technology to target and clear certain immune cells (B cells) that are causing the di…

This early study tests a new treatment called CD19 UCAR-T cells for people with autoimmune diseases like lupus, vasculitis, and Sjögren's syndrome. The therapy uses modified immune cells to target and calm the overactive immune system. The main goals are to check safety and see i…

This study tests whether a low-gluten diet, tailored to a person's genetic makeup, can help manage systemic lupus erythematosus (SLE). Researchers will screen 100 lupus patients for specific genes (HLA-DQ2 or DQ8) and then randomly assign those who test positive to either a low-g…

This study tests a new treatment using CD19 CAR T-cells for people with severe autoimmune diseases that haven't improved with standard therapies. About 30 participants will receive a single dose of these engineered immune cells after chemotherapy. The goal is to see if it's safe …

Lupus nephritis is a serious kidney complication of lupus that can lead to kidney failure. This study investigates whether levels of neutrophil extracellular traps (NETs)—web-like structures released by immune cells—in the blood can predict how well patients respond to therapy. R…

This study looks at whether a 12-session weekly yoga program, added to usual medical care, can help adults with systemic autoimmune and inflammatory diseases (like lupus) feel less tired, have less pain, and improve their mood. Researchers will also check if yoga helps people sti…

This study looks at whether a 12-week aerobic exercise program can improve thinking skills and reduce disease activity in people with lupus. Researchers will test memory, attention, and walking ability before and after the program. The goal is to see if exercise can ease lupus-re…

This study looks at whether two substances in the blood, IL-6 and MMP-7, can help doctors diagnose and predict the course of a rare lung disease in children. Researchers will measure these markers in 60 children with immune-mediated interstitial lung disease and compare them to h…

This study will look at how the lupus medication Saphnelo (anifrolumab) is being used in women aged 15 to 50 who could become pregnant. Researchers will track how many women use the drug each year and describe their health characteristics. The goal is to gather real-world informa…

This early-stage study will test the safety and tolerability of a new drug called ACT100 in 48 healthy adults. Participants will receive either the drug or a placebo, and researchers will monitor for side effects and measure how the drug moves through the body. This is the first …

This study aims to better understand why some people's immune cells attack their own body, causing autoimmune diseases like lupus and scleroderma. Researchers will analyze blood samples from 200 adults with these conditions to identify and measure specific harmful immune cells. T…

This study will collect health information, samples, and data from 100 people in Luxembourg (800 total across Europe) who have rheumatoid diseases and are starting or changing treatment. Researchers hope to find patterns that can predict which treatments work best for each person…